Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

This study is testing venetoclax, a targeted drug that blocks a cancer-survival protein, combined with intensive chemotherapy for younger and middle-aged adults with newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. Venetoclax is already used with milder chemotherapy in older patients, and this study tests whether it can improve outcomes when paired with stronger regimens in people who can tolerate them. **You may be eligible if...** - You are between 14 and 60 years old with newly diagnosed AML (not previously treated) - Your physical status is good (ECOG 0–2) - Your heart function, liver function, and kidney function meet minimum levels - You have given informed consent (or a legal guardian has, if needed) **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific subtype) or AML with BCR-ABL fusion - You have previously received treatment for AML (except white blood cell-reducing drugs like hydroxyurea) - You have active heart disease (angina, recent heart attack, significant arrhythmia, or heart failure) - You have a serious active infection (like tuberculosis or aspergillosis) - You have another active cancer requiring treatment at the same time Talk to your doctor to see if this trial is right for you.